Lufax Holding heads into the final week of September with a split personality: the stock gained 7.8% on the week yet closed at just $1.24, while options traders have shifted meaningfully toward downside protection and short sellers have quietly rebuilt positions through the month.
The sharpest signal this week is in options. The put/call ratio has climbed to 0.89, well above its 20-day average of 0.72 and roughly 1.25 standard deviations through that mean. The move is notable for its speed. Through early September the ratio sat anchored in the low 0.62 range. Then, from September 21 onward, it jumped to the high 0.89-to-0.92 range where it has held all week. That step-change in protective demand coincides almost exactly with the stock's late-September bounce, suggesting options buyers are treating the rally as an opportunity to hedge rather than a reason to press long.
Short interest tells a broadly consistent story. Shorts have added steadily through September, with the estimated share count rising 23% over the past month to just over 5.1 million shares. The weekly change alone was 13.3%, concentrated largely in a single jump around September 23. The borrow market remains entirely relaxed, however: availability is running at 568% of short interest, meaning there are roughly five and a half shares available to borrow for every one already shorted. Cost to borrow has also eased sharply, down 35% over the past month to just 0.57%. With borrow this loose and this cheap, the short build looks deliberate rather than desperate, there is no evidence of any supply squeeze forcing either side of the trade.
The Street is cautious with a constructive tilt, though most of the published targets look difficult to reconcile with the current $1.24 price. JP Morgan's Katherine Lei upgraded the stock to Overweight in late July with a $2.00 target, having already moved from Underweight to Neutral in April. That is the most recent significant action, and it points in a bullish direction, but it still implies the stock would need to more than double from here. Other targets on the register run higher still and date from 2024, when the stock traded at very different levels. The valuation picture is unusual: price-to-book is just 0.085, and the earnings yield is running around 8.4%, reflecting a deeply discounted multiple on a company whose growth profile has deteriorated sharply in recent years. EV/EBITDA has contracted almost 1.8 turns over the past 30 days. The ORTEX short score of 43 puts Lufax in roughly the middle of the universe, not an extreme reading in either direction.
Ownership is the single most defining structural fact about this stock. Ping An Insurance, which holds a Schedule 13D activist position last updated August 28, controls 73.3% of the class. That is not a liquid float in any conventional sense. With Ping An's stake and Tun Kung's 7.8% holding, the two largest owners alone account for more than 80% of shares. The relevant disclosure caveat applies: 13D/G stakes are event-driven around the 5% threshold, and positions are as last disclosed. Norges Bank cut its position by more than 7 million shares in the second quarter, the largest recent institutional move among minority holders, and Acadian trimmed by roughly 1.3 million shares over the same period.
The next earnings date is November 19. The two most recent prints both drew negative reactions: the August 2026 result produced a one-day drop of 8.5% and a five-day loss of 15%. The print before that moved flat on the day but fell 7.6% over five sessions. That pattern of delayed selling after results, rather than sharp day-one reversals, is worth tracking into November alongside whether the current short build and defensive options positioning shift before the release date.
See the live data behind this article on ORTEX.
Open LU on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
